Novartis receives FDA approval 177Lu-PSMA-617 for metastatic castration resistant prostate cancer


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
FDA breakthrough therapy for Novartis metastatic prostate cancer drug

Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to 177 Lu-PSMA-617, an investigational radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Breakthrough Therapy designation is granted to medicines being evaluated for serious conditions where early clinical evidence indicates the potential for substantial improvement over available therapy1.

Breakthrough therapy designation granted based on positive data from the pivotal, Phase III VISION study evaluating 177 Lu-PSMA-617, a targeted radioligand therapy, plus standard of care (SOC), compared to SOC alone, in patients with progressive PSMA-positive mCRPC2.


Phase III VISION study demonstrated that 177 Lu-PSMA-617 significantly improved overall survival and radiographic progression-free survival for men with progressive PSMA-positive mCRPC2
The five-year survival rate for patients with metastatic prostate cancer is approximate 30%.

Novartis is a global leader in radioligand therapy, uniquely positioned with broad commercial experience, established manufacturing and supply chain capabilities, and extensive development expertise

Two additional studies with 177 Lu-PSMA-617 radioligand therapy in earlier lines of treatment for metastatic prostate cancer are ongoing, investigating potential clinical utility in the mCRPC pre-taxane setting (PSMAfore) and in the metastatic hormone-sensitive setting (PSMAddition).

Tags : #Prostate #metastaticProstateCancer #FDAApproval #FDANewsLatest #Novartis

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

ACT Fibernet Collaborates with Amazon Prime to Offer Prime Lite Benefits to Consumers June 19, 2025
CARE Hospitals Conducts “The Power of 3” Public Awareness Drive at Punjagutta JunctionJune 19, 2025
Legalising key population led health services in Thailand is a gamechangerJune 19, 2025
MGM Healthcare Successfully Performs Rare Endoscopic Skull Base Surgery on a 1-Year-Old with Brain Herniation inside NoseJune 19, 2025
Asian Paints’ Apcolite All Protek redefines the Gold Standard in Interior Paints with Breakthrough ‘Lotus Effect Technology’June 19, 2025
The Soft Touch of Tomorrow: Rural India's Lives Are Being Changed by 3D-Printed LimbsJune 19, 2025
QNET India Celebrates International Yoga Day with Curated Wellness EssentialsJune 18, 2025
illumine Raises $2.5M Seed Funding to Globally Scale Vertical AI Platform for Childcare ManagementJune 18, 2025
Mykare Achieves EBITDA-Positive Status in Elective Surgery Vertical with 80% Revenue GrowthJune 18, 2025
HCG Manavata Cancer Centre Launches Scalp Cooling Therapy To Prevent Chemotherapy-Induced Hair LossJune 18, 2025
Biohacking in India: From Blue Light Glasses to Metabolic TrackingJune 18, 2025
AI-Generated Prescriptions: Will They Ever Be Safe Enough?June 18, 2025
The Role of Panchayats in Public Health: Untapped Potential in Rural GovernanceJune 18, 2025
When Medicines Stop Working: How Communities in India Are Fighting BackJune 18, 2025
Archish Fertility & IVF, India’s First 100% Fully Transparent Fertility Lab, Partners with Amaha Health for Holistic Patient Support & Mental WellbeingJune 17, 2025
Supporting Mental Health in AutismJune 17, 2025
New guidelines for monitoring IBD patients to prevent bowel cancerJune 17, 2025
TTK Prestige Launches Tri-Ply Hexamagic Cookware, Blending Non-Stick Innovation with Triply DurabilityJune 17, 2025
Turning ₹2.35 Crore of Grant into ₹17.9 Crore of Impact: How Villgro-360 ONE’s Capital For Impact is Benefitting Thousands of Marginalised FarmersJune 17, 2025
Online Chikitsa Mitra Rolls Out Mobile App for Specialized, In-Home HealthcareJune 17, 2025